Annualized relapse rates are lower for patients with relapsing MS receiving anti-CD20 monoclonal antibody ofatumumab compared with teriflunomide.
The COVID-19 pandemic is having an impact on the psychological health of patients with relapsing-remitting multiple sclerosis.
For patients with secondary progressive multiple sclerosis, relapses are associated with accelerated disability progression.
Repeated transcranial direct current stimulation over 5 days was able to reduce pain intensity in patients with chronic neuropathic pain due to multiple sclerosis.
Researchers confirmed the effectiveness of ocrelizumab in the treatment of relapsing-remitting and progressive MS, and found significant influence of BMI on B-cell repopulation.
Compromise of long-term cognitive function and neuronal integrity are associated with vitamin D deficiency and smoking in patients with MS.
In addition to common cerebral hemodynamic changes, patients with MS were found to have reduced CVR when compared with healthy controls.
For people with multiple sclerosis, there has been an increase in use of complementary and alternative medicine between 2001 and 2018.
Patients with severe MS treated with alemtuzumab displayed milder and shorter symptoms of COVID-19.
For patients with MS, age, obesity, and high Expanded Disability Severity Scale score are significantly associated with increased risk for severe COVID-19.